Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBER: Patiromer for Spironolactone Enablement in Resistant Hypertension and CKD
NCT03071263Phase 2Completed
- Sponsor
- Relypsa, Inc.
- Start
- Jan 2017
- Primary completion
- Nov 2018
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of patiromer in hyperkalemia, sponsored by Relypsa, Inc.. Started Jan 2017; status: completed.
02
Drugs
patiromer
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT03071263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071263.